162 related articles for article (PubMed ID: 21919619)
1. Confronting the barriers to develop novel vaccines against brucellosis.
Oliveira SC; Giambartolomei GH; Cassataro J
Expert Rev Vaccines; 2011 Sep; 10(9):1291-305. PubMed ID: 21919619
[TBL] [Abstract][Full Text] [Related]
2. Escheriosome-mediated delivery of recombinant ribosomal L7/L12 protein confers protection against murine brucellosis.
Mallick AI; Singha H; Khan S; Anwar T; Ansari MA; Khalid R; Chaudhuri P; Owais M
Vaccine; 2007 Nov; 25(46):7873-84. PubMed ID: 17931756
[TBL] [Abstract][Full Text] [Related]
3. Research progress in live attenuated Brucella vaccine development.
Wang Z; Wu Q
Curr Pharm Biotechnol; 2013; 14(10):887-96. PubMed ID: 24372253
[TBL] [Abstract][Full Text] [Related]
4. Venezuelan field trials of vaccines against brucellosis in swine.
Lord VR; Cherwonogrodzky JW; Schurig GG; Lord RD; Marcano MJ; Meléndez GE
Am J Vet Res; 1998 May; 59(5):546-51. PubMed ID: 9582954
[TBL] [Abstract][Full Text] [Related]
5. Liposomised recombinant ribosomal L7/L12 protein protects BALB/c mice against Brucella abortus 544 infection.
Mallick AI; Singha H; Chaudhuri P; Nadeem A; Khan SA; Dar KA; Owais M
Vaccine; 2007 May; 25(18):3692-704. PubMed ID: 17296251
[TBL] [Abstract][Full Text] [Related]
6. Lipopolysaccharide as a target for brucellosis vaccine design.
Conde-Álvarez R; Arce-Gorvel V; Gil-Ramírez Y; Iriarte M; Grilló MJ; Gorvel JP; Moriyón I
Microb Pathog; 2013 May; 58():29-34. PubMed ID: 23219811
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of vaccination strategies against intranasal challenge with Brucella abortus in BALB/c mice.
Surendran N; Sriranganathan N; Lawler H; Boyle SM; Hiltbold EM; Heid B; Zimmerman K; Witonsky SG
Vaccine; 2011 Mar; 29(15):2749-55. PubMed ID: 21316499
[TBL] [Abstract][Full Text] [Related]
8. Comparative study of the immunobiological properties of live brucellosis vaccines.
Salmakov KM; Fomin AM; Plotnikova EM; Safina GM; Galimova GM; Salmakova AV; Ivanov AV; Panin AN; Sklyarov OD; Shumilov KV; Klimanov AI
Vaccine; 2010 Oct; 28 Suppl 5():F35-40. PubMed ID: 20362201
[TBL] [Abstract][Full Text] [Related]
9. Enhanced efficacy of recombinant Brucella abortus RB51 vaccines against B. melitensis infection in mice.
Vemulapalli R; Contreras A; Sanakkayala N; Sriranganathan N; Boyle SM; Schurig GG
Vet Microbiol; 2004 Sep; 102(3-4):237-45. PubMed ID: 15327798
[TBL] [Abstract][Full Text] [Related]
10. Protection of BALB/C mice against Brucella abortus 544 challenge by vaccination with combination of recombinant human serum albumin-l7/l12 (Brucella abortus ribosomal protein) and lipopolysaccharide.
Pakzad I; Rezaee A; Rasaee MJ; Hossieni AZ; Tabbaraee B; Kazemnejad A
Roum Arch Microbiol Immunol; 2010; 69(1):5-12. PubMed ID: 21053778
[TBL] [Abstract][Full Text] [Related]
11. Immunization with recombinant Brucella species outer membrane protein Omp16 or Omp19 in adjuvant induces specific CD4+ and CD8+ T cells as well as systemic and oral protection against Brucella abortus infection.
Pasquevich KA; Estein SM; García Samartino C; Zwerdling A; Coria LM; Barrionuevo P; Fossati CA; Giambartolomei GH; Cassataro J
Infect Immun; 2009 Jan; 77(1):436-45. PubMed ID: 18981242
[TBL] [Abstract][Full Text] [Related]
12. Towards a Brucella vaccine for humans.
Perkins SD; Smither SJ; Atkins HS
FEMS Microbiol Rev; 2010 May; 34(3):379-94. PubMed ID: 20180858
[TBL] [Abstract][Full Text] [Related]
13. Increases of efficacy as vaccine against Brucella abortus infection in mice by simultaneous inoculation with avirulent smooth bvrS/bvrR and rough wbkA mutants.
Grilló MJ; Manterola L; de Miguel MJ; Muñoz PM; Blasco JM; Moriyón I; López-Goñi I
Vaccine; 2006 Apr; 24(15):2910-6. PubMed ID: 16439039
[TBL] [Abstract][Full Text] [Related]
14. Rough vaccines in animal brucellosis: structural and genetic basis and present status.
Moriyón I; Grilló MJ; Monreal D; González D; Marín C; López-Goñi I; Mainar-Jaime RC; Moreno E; Blasco JM
Vet Res; 2004; 35(1):1-38. PubMed ID: 15099501
[TBL] [Abstract][Full Text] [Related]
15. Co-immunization with interlukin-18 enhances the protective efficacy of liposomes encapsulated recombinant Cu-Zn superoxide dismutase protein against Brucella abortus.
Singha H; Mallick AI; Jana C; Fatima N; Owais M; Chaudhuri P
Vaccine; 2011 Jun; 29(29-30):4720-7. PubMed ID: 21565241
[TBL] [Abstract][Full Text] [Related]
16. Over-expression of homologous antigens in a leucine auxotroph of Brucella abortus strain RB51 protects mice against a virulent B. suis challenge.
Rajasekaran P; Surendran N; Seleem MN; Sriranganathan N; Schurig GG; Boyle SM
Vaccine; 2011 Apr; 29(17):3106-10. PubMed ID: 21376799
[TBL] [Abstract][Full Text] [Related]
17. Adverse events in humans associated with accidental exposure to the livestock brucellosis vaccine RB51.
Ashford DA; di Pietra J; Lingappa J; Woods C; Noll H; Neville B; Weyant R; Bragg SL; Spiegel RA; Tappero J; Perkins BA
Vaccine; 2004 Sep; 22(25-26):3435-9. PubMed ID: 15308369
[TBL] [Abstract][Full Text] [Related]
18. A recombinant subunit vaccine based on the insertion of 27 amino acids from Omp31 to the N-terminus of BLS induced a similar degree of protection against B. ovis than Rev.1 vaccination.
Cassataro J; Pasquevich KA; Estein SM; Laplagne DA; Velikovsky CA; de la Barrera S; Bowden R; Fossati CA; Giambartolomei GH; Goldbaum FA
Vaccine; 2007 May; 25(22):4437-46. PubMed ID: 17442465
[TBL] [Abstract][Full Text] [Related]
19. A recent trial comparing two 45/20 adjuvant Brucella vaccines.
McKeon FW
Dev Biol Stand; 1976; 31():343-50. PubMed ID: 816690
[TBL] [Abstract][Full Text] [Related]
20. [The application and research advances of Brucella vaccines].
Ding JB; Mao KR; Cheng JS; Dai ZH; Jiang YW
Wei Sheng Wu Xue Bao; 2006 Oct; 46(5):856-9. PubMed ID: 17172046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
